Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

Provided By GlobeNewswire

Last update: Oct 7, 2025

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE^® (relugolix/estradiol/norethindrone acetate) in Canada.